title: PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS)
abstract: BACKGROUND
  Percutaneous transluminal coronary angioplasty (PTCA) with its various manipulations could create a dangerous, sudden haemostatic response. This study was performed to investigate PTCA-induced periprocedural changes in platelet activation and its consequences.
  
  
  METHODS
  Twenty-five consecutive patients admitted for elective PTCA were preclassified as having or not having circulating activated platelets. Blood samples were taken for platelet activation marker analysis before, six times during and 2 h after PTCA. Intravascular platelet activation was analysed by flow cytometry to measure activation-dependent surface markers thrombospondin, P-selectin (CD62) and lysosomal GP53 (CD63).
  
  
  RESULTS
  PTCA was associated with a significant reduction of peripheral platelet count. The initiation of the PTCA procedure led to a significant loss of more than 50% of the degranulated, activated platelets. After PTCA, the number of degranulated, activated platelets uniformly increased.
  
  
  CONCLUSIONS
  We conclude that PTCA can induce consumption, particularly of preactivated platelets, and lead to sustained platelet activation after the procedure. This might explain why preactivated patients are at increased risk of suffering periprocedural ischaemic events and why increased thrombogenicity favours acute flow disruption and the progression of coronary stenosis at the lesion site.
authors.affiliation: Diabetes Research Institute, Heinrich Heine University, Duesseldorf, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Kolarov
authors.forename: D
authors.initials: D
authors.lastname: Tschoepe
authors.forename: H K
authors.initials: HK
authors.lastname: Nieuwenhuis
authors.forename: F A
authors.initials: FA
authors.lastname: Gries
authors.forename: B
authors.initials: B
authors.lastname: Strauer
authors.forename: H P
authors.initials: HP
authors.lastname: Schultheiss
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D015703:Antigens, CD / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000502:physiology*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D015539:Platelet Activation / Q000502:physiology*; D010976:Platelet Count; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism; D060149:Tetraspanin 30; D019699:Thrombospondins
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; C554586:CD63 protein, human; D008562:Membrane Glycoproteins; D019007:P-Selectin; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D019699:Thrombospondins